Autologous tumour cell vaccine - Champions Oncology/Gradalis/Mary Crowley

Drug Profile

Autologous tumour cell vaccine - Champions Oncology/Gradalis/Mary Crowley

Alternative Names: Bi-shRNAfurin; bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy; FANG vaccine; FANG™; TAG vaccine; TGFbeta2 antisense + rhGMCSF vaccine; Vigil™; Vigil™ EATC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gradalis
  • Developer Gradalis; Mary Crowley Cancer Research Center
  • Class Cancer vaccines; Tumour cell vaccines
  • Mechanism of Action Furin expression inhibitors; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II/III Breast cancer
  • Phase II Ewing's sarcoma; Gynaecological cancer; Liver metastases; Malignant melanoma
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal, Injection)
  • 01 Sep 2017 Gradalis completes a phase I trial in Malignant melanoma (Second-line therapy or greater, Combination therapy) in USA (NCT02574533)
  • 28 Jul 2017 Gradalis terminates a phase II trial due to a business decision to pursue other indications in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (NCT01453361)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top